The following is a summary of “Elevated serum concentrations of GFAP in hereditary transthyretin amyloidosis since pre-symptomatic stages,” published in the April 2025 issue of Journal of Neurology by ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease. Using new ...

There are three major subtypes of amyloidosis: primary amyloidosis, secondary amyloidosis, and hereditary amyloidosis (Khan & Falk, 2001; Nakata & Shimamoto, 2003; Smith, 2003). Primary ...

Amvuttra (vutrisiran) is a prescription drug that’s used to treat nerve damage and weakened heart muscles related to a condition called ATTR amyloidosis. Amvuttra is given as an injection under ...

Lowering levels of circulating transthyretin with vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) decreased their risk for mortality and cardiovascular events ...

The interventricular septum brightness index obtained from the apical 4-chamber view was higher in patients with ATTR-CM compared to patients with hypertensive heart disease and those with light chain ...

Dr Lal Pathlabs has introduced Amyloid Typing by Laser Capture Microdissection & Mass Spectrometry a breakthrough test for accurately identifying different types of Amyloid proteins. With this launch, ...

Medical testing laboratory Dr. Lal PathLabs said on Tuesday that it has become south Asia’s first diagnostic chain to offer an advance test for amyloidosis, a rare but critical disease caused by ...